<i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome
There is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/2/1321 |
| _version_ | 1797339742060150784 |
|---|---|
| author | Ignacio Goyache Deyan Yavorov-Dayliev Fermín I. Milagro Paula Aranaz |
| author_facet | Ignacio Goyache Deyan Yavorov-Dayliev Fermín I. Milagro Paula Aranaz |
| author_sort | Ignacio Goyache |
| collection | DOAJ |
| description | There is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and insulin homeostasis, probiotics with beneficial properties have emerged as an alternative therapeutic tool to ameliorate metabolic diseases-related disturbances, including fat excess or inflammation. In the last few years, different strains of bacteria, mainly lactic acid bacteria (LAB) and species from the genus <i>Bifidobacterium</i>, have emerged as potential probiotics due to their anti-obesogenic and/or anti-diabetic properties. However, in vivo studies are needed to demonstrate the mechanisms involved in these probiotic features. In this context, <i>Caenorhabditis elegans</i> has emerged as a very powerful simple in vivo model to study the physiological and molecular effects of probiotics with potential applications regarding the different pathologies of metabolic syndrome. This review aims to summarize the main studies describing anti-obesogenic, anti-diabetic, or anti-inflammatory properties of probiotics using <i>C. elegans</i> as an in vivo research model, as well as providing a description of the molecular mechanisms involved in these activities. |
| first_indexed | 2024-03-08T09:52:45Z |
| format | Article |
| id | doaj.art-528da07446054cda91a40ce36ad5c736 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T09:52:45Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-528da07446054cda91a40ce36ad5c7362024-01-29T13:59:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-01252132110.3390/ijms25021321<i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic SyndromeIgnacio Goyache0Deyan Yavorov-Dayliev1Fermín I. Milagro2Paula Aranaz3Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, SpainFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, SpainFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, SpainFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, SpainThere is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and insulin homeostasis, probiotics with beneficial properties have emerged as an alternative therapeutic tool to ameliorate metabolic diseases-related disturbances, including fat excess or inflammation. In the last few years, different strains of bacteria, mainly lactic acid bacteria (LAB) and species from the genus <i>Bifidobacterium</i>, have emerged as potential probiotics due to their anti-obesogenic and/or anti-diabetic properties. However, in vivo studies are needed to demonstrate the mechanisms involved in these probiotic features. In this context, <i>Caenorhabditis elegans</i> has emerged as a very powerful simple in vivo model to study the physiological and molecular effects of probiotics with potential applications regarding the different pathologies of metabolic syndrome. This review aims to summarize the main studies describing anti-obesogenic, anti-diabetic, or anti-inflammatory properties of probiotics using <i>C. elegans</i> as an in vivo research model, as well as providing a description of the molecular mechanisms involved in these activities.https://www.mdpi.com/1422-0067/25/2/1321gut microbiotapostbioticsobesityinsulin resistancediabetescardiovascular disease |
| spellingShingle | Ignacio Goyache Deyan Yavorov-Dayliev Fermín I. Milagro Paula Aranaz <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome International Journal of Molecular Sciences gut microbiota postbiotics obesity insulin resistance diabetes cardiovascular disease |
| title | <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome |
| title_full | <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome |
| title_fullStr | <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome |
| title_full_unstemmed | <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome |
| title_short | <i>Caenorhabditis elegans</i> as a Screening Model for Probiotics with Properties against Metabolic Syndrome |
| title_sort | i caenorhabditis elegans i as a screening model for probiotics with properties against metabolic syndrome |
| topic | gut microbiota postbiotics obesity insulin resistance diabetes cardiovascular disease |
| url | https://www.mdpi.com/1422-0067/25/2/1321 |
| work_keys_str_mv | AT ignaciogoyache icaenorhabditiselegansiasascreeningmodelforprobioticswithpropertiesagainstmetabolicsyndrome AT deyanyavorovdayliev icaenorhabditiselegansiasascreeningmodelforprobioticswithpropertiesagainstmetabolicsyndrome AT ferminimilagro icaenorhabditiselegansiasascreeningmodelforprobioticswithpropertiesagainstmetabolicsyndrome AT paulaaranaz icaenorhabditiselegansiasascreeningmodelforprobioticswithpropertiesagainstmetabolicsyndrome |